A dual B cell cytokine antagonist of BAFF and APRIL with best-in-class potential

ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases. Engineered by directed evolution, ALPN-303 potently inhibits the pleiotropic B cell cytokines B cell activating factor (BAFF, BLyS) and a proliferation inducing ligand (APRIL), which play key roles in B cell development, differentiation, and survival, and together contribute to the pathogenesis of B cell-related autoimmune diseases like systemic lupus erythematosus (SLE), Sjögren’s syndrome, inflammatory arthritis, multiple sclerosis, and many others. By simultaneously blocking these two cytokines, ALPN-303 has the potential to improve outcomes in patients suffering from severe autoimmune and/or inflammatory diseases.

ALPN-303: An Engineered Inhibitor of BAFF and APRIL for B Cell Mediated Inflammatory Diseases

ALPN-303 Appears Superior to Existing BAFF/APRIL Inhibitors in vitro

ALPN-303 Exhibits Encouraging Preclinical Efficacy in Connective Tissue Disease

The best-in-class potential of ALPN-303 is supported by research presented at the  2021 EULAR Virtual Congress demonstrating that ALPN-303:

  • Appears more potent than existing BAFF and APRIL inhibitors in vitro and in vivo
  • In models of lupus and Sjögren’s syndrome, reduces key markers of renal disease and sialoadenitis relative to controls

For additional information please refer to our corporate filings, corporate presentation, and Scientific Publications.